105 related articles for article (PubMed ID: 2873234)
1. Quantitation of the ultra short acting beta-adrenergic antagonist flestolol in blood by liquid chromatography.
Moore P; Mai K; Lai CM
J Pharm Sci; 1986 Apr; 75(4):424-6. PubMed ID: 2873234
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and pharmacodynamics of flestolol, a new short-acting, beta-adrenergic receptor antagonist.
Achari R; Drissel D; Hulse JD; Bell V; Turlapaty P; Laddu A; Matier WL
J Clin Pharmacol; 1987 Jan; 27(1):60-4. PubMed ID: 2890664
[TBL] [Abstract][Full Text] [Related]
3. Antiarrhythmic activity of flestolol, a novel ultra-short-acting beta-adrenoceptor antagonist, in the dog.
Reynolds RD; Brown BS
Eur J Pharmacol; 1986 Nov; 131(1):55-66. PubMed ID: 2880726
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of flestolol in man: preliminary data.
Achari R; Hulse JD; Drissel D; Matier WL
Br J Clin Pharmacol; 1985 Dec; 20(6):691-4. PubMed ID: 2868745
[TBL] [Abstract][Full Text] [Related]
5. Flestolol: an ultra-short-acting beta-adrenergic blocking agent.
Barton SD; Burge J; Turlapaty P; Laddu AR
J Clin Pharmacol; 1986 Mar; 26(S1):A36-A39. PubMed ID: 2870085
[TBL] [Abstract][Full Text] [Related]
6. Tolerance and beta-adrenergic blocking activity of flestolol, a short-acting beta blocker.
Turlapaty P; Burge J; Hulse J; Achari R; Bell V; Mosberg H; Laddu A
Clin Pharmacol Ther; 1986 May; 39(5):543-9. PubMed ID: 3698462
[TBL] [Abstract][Full Text] [Related]
7. Hemodynamic effects of flestolol, a titratable short-acting intravenous beta-adrenergic receptor blocker.
Strom J; Josephson M; Frishman WH; Singh B; Heilbrunn S; Osterle S; Turlapaty P; Viray R; Coe J; Bell V
J Clin Pharmacol; 1988 Mar; 28(3):276-82. PubMed ID: 2896204
[TBL] [Abstract][Full Text] [Related]
8. Verification of a canine model of transient exercise induced myocardial dysfunction: antianginal effects of flestolol, an ultra short acting beta adrenoceptor antagonist.
Fischer G; Grohs JG; Raberger G
Cardiovasc Res; 1990 Feb; 24(2):115-20. PubMed ID: 1970278
[TBL] [Abstract][Full Text] [Related]
9. Controlled beta-receptor blockade with flestolol: a novel ultrashort-acting beta-blocker.
Murthy VS; Hwang TF; Rosen LB; Gorczynski RJ
J Cardiovasc Pharmacol; 1987 Jan; 9(1):72-8. PubMed ID: 2434798
[TBL] [Abstract][Full Text] [Related]
10. Effects of flestolol, an ultra-short acting beta-adrenoceptor antagonist, on hemodynamic changes produced by treadmill exercise or isoprenaline stimulation in conscious dogs.
Grohs JG; Fischer G; Raberger G
J Cardiovasc Pharmacol; 1990 Feb; 15(2):175-81. PubMed ID: 1689410
[TBL] [Abstract][Full Text] [Related]
11. Clinical electrophysiology of flestolol, a potent ultra short-acting beta blocker.
Swerdlow CD; Peterson J; Turlapaty P
Am Heart J; 1986 Jan; 111(1):49-53. PubMed ID: 2868646
[TBL] [Abstract][Full Text] [Related]
12. A high-performance liquid chromatographic assay for the enantiomers of bevantolol in human plasma.
Rose SE; Randinitis EJ
Pharm Res; 1991 Jun; 8(6):758-62. PubMed ID: 1676512
[TBL] [Abstract][Full Text] [Related]
13. Estimation of carvedilol in human plasma by using HPLC-fluorescence detector and its application to pharmacokinetic study.
Rathod R; Prasad LP; Rani S; Nivsarkar M; Padh H
J Chromatogr B Analyt Technol Biomed Life Sci; 2007 Oct; 857(2):219-23. PubMed ID: 17702675
[TBL] [Abstract][Full Text] [Related]
14. Gas chromatographic-mass spectrometric assay for the ultra-short-acting beta-blocker esmolol.
Sum CY; Yacobi A
J Pharm Sci; 1984 Aug; 73(8):1177-9. PubMed ID: 6149299
[TBL] [Abstract][Full Text] [Related]
15. Determination of falintolol, a new aliphatic beta-adrenergic antagonist, in whole blood by gas chromatography with electron-capture detection: geometric isomers resolution.
Himber J; Andermann G; Bouzoubaa M; Leclerc G
J Chromatogr Sci; 1987 Jan; 25(1):33-7. PubMed ID: 2880859
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of flestolol, a new ultrashort-acting beta-adrenergic blocking agent, for supraventricular tachyarrhythmias.
Steinberg JS; Katz RJ; Somberg JC; Keefe D; Laddu AR; Burge J
Am J Cardiol; 1986 Nov; 58(10):1005-8. PubMed ID: 2877563
[TBL] [Abstract][Full Text] [Related]
17. Simultaneous determination of the enantiomers of esmolol and its acid metabolite in human plasma by reversed phase liquid chromatography with solid-phase extraction.
Tang YH; He Y; Yao TW; Zeng S
J Chromatogr B Analyt Technol Biomed Life Sci; 2004 Jun; 805(2):249-54. PubMed ID: 15135097
[TBL] [Abstract][Full Text] [Related]
18. High-performance liquid chromatographic assay for the major blood metabolite of esmolol--an ultra short acting beta blocker.
Stampfli HF; Lai CM; Yacobi A; Sum CY
J Chromatogr; 1984 Jul; 309(1):203-8. PubMed ID: 6148350
[No Abstract] [Full Text] [Related]
19. High-performance liquid chromatographic assay for the experimental anticancer agent oxantrazole.
Frank SK; Mathiesen DA; Whitfield LR; Ames MM
J Chromatogr; 1987 Aug; 419():225-32. PubMed ID: 3667780
[TBL] [Abstract][Full Text] [Related]
20. High-performance liquid chromatographic method for determination of ronactolol in urine and plasma: evaluation of pharmacokinetic parameters in healthy humans.
Mannucci C; Caviglioli G; Perico A; Triolo A
J Pharm Sci; 1992 Jun; 81(6):556-8. PubMed ID: 1355791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
